Coeptis Therapeutics (NASDAQ:COEP) Announces Quarterly Earnings Results

Coeptis Therapeutics (NASDAQ:COEP) posted its earnings results on Thursday. The company reported ($0.12) EPS for the quarter, FiscalAI reports. The business had revenue of $0.86 million during the quarter.

Coeptis Therapeutics Price Performance

Shares of NASDAQ:COEP opened at $11.30 on Friday. The business’s fifty day moving average price is $12.60 and its two-hundred day moving average price is $14.29. The stock has a market cap of $60.34 million, a PE ratio of -3.95 and a beta of -0.49. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.21 and a current ratio of 2.21. Coeptis Therapeutics has a one year low of $6.26 and a one year high of $21.41.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Coeptis Therapeutics in a research note on Wednesday, January 21st. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock has an average rating of “Sell”.

Institutional Trading of Coeptis Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in COEP. Steward Partners Investment Advisory LLC increased its position in Coeptis Therapeutics by 100.0% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 5,000 shares of the company’s stock worth $71,000 after purchasing an additional 2,500 shares in the last quarter. Yorkville Advisors Global LP acquired a new stake in shares of Coeptis Therapeutics during the 3rd quarter worth about $140,000. Marshall Wace LLP acquired a new stake in shares of Coeptis Therapeutics during the 4th quarter worth about $259,000. State Street Corp grew its holdings in shares of Coeptis Therapeutics by 35.0% during the fourth quarter. State Street Corp now owns 26,830 shares of the company’s stock worth $382,000 after buying an additional 6,962 shares in the last quarter. Finally, Geode Capital Management LLC raised its position in shares of Coeptis Therapeutics by 12.6% in the fourth quarter. Geode Capital Management LLC now owns 42,097 shares of the company’s stock valued at $600,000 after buying an additional 4,721 shares during the last quarter. 13.88% of the stock is currently owned by hedge funds and other institutional investors.

Coeptis Therapeutics Company Profile

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.